Tethered nanoparticles make tumour cells more vulnerable

Posted By : Enaie Azambuja
Tethered nanoparticles make tumour cells more vulnerable

MIT researchers have devised a way to make tumour cells more susceptible to certain types of cancer treatment by coating the cells with nanoparticles before delivering drugs. By tethering hundreds of tiny particles to the surfaces of tumour cells in the presence of a mechanical force, the researchers made the cells much more vulnerable to attack by a drug that triggers cancer cells to commit suicide.

It appears that the tethered nanoparticles increase the forces exerted on the cells by flowing blood, which makes the cells more likely to die. “When you attach many particles to the membranes of these cells, and then expose them to forces that mimic those in the human body, like blood flow, these therapeutics become more effective. It’s a way of amplifying the forces on the cells using polymeric materials,” says Michael Mitchell, a postdoc at MIT’s Koch Institute for Integrative Cancer Research and the lead author of the study.

In tests in mice, the researchers found that the tethered nanoparticles made the cell-suicide-inducing drug 50% more effective, and this combination eliminated up to 90% of tumour cells in the mice.

Robert Langer, the David H. Koch Institute Professor at MIT, is the senior author of the paper, which appears in Nature Communications. In addition to studying tumours’ abnormal genetic and biochemical traits, scientists and engineers in recent years have examined how tumours’ physical characteristics contribute to disease progression.

Solid tumours exploit physical forces, such as their increased stiffness and altered blood flow, to enhance their survival and growth. Forces exerted by flowing blood and fluid in soft tissues also affect the behavior of cancer and a variety of host cells.

In the new study, the MIT team set out to determine whether physical forces such as those exerted by blood flow might influence how tumours respond to drug treatment. They focused on an experimental drug known as TRAIL, which is a protein expressed on different cells of the immune system.

TRAIL is a member of a family of tumour necrosis factors that bind to death receptors on cell membranes, sending them a signal that stimulates apoptosis, or programmed cell death.

Initial experiments revealed that tumour cells became more susceptible to this drug after being exposed to shear forces from physiological fluids. “Under these flow conditions, more tumour cells began to die in the presence of the therapeutic,” Mitchell says.

That led the researchers to hypothesise that they could make cells even more susceptible to the treatment by increasing the forces acting on them. One way to do that is to attach tiny particles to the cell surfaces.

Acting like balls on a string, the tethered particles batter and tug at the tumour cell surface as blood flows by, making the cells more susceptible to the cell death signal from the drug.

The particles, which can be injected into the bloodstream, are made of biodegradable polymers known as PLGA. These particles are coated with another polymer, PEG, that is tagged with a ligand or antibody specific to proteins found on tumour cell surfaces, which allows them to be tethered onto the surface.

In tests in mice, the researchers found that attaching particles to tumour cells and then treating them with TRAIL killed metastatic tumour cells in the bloodstream and also reduced the progression of solid tumours in mice.

The researchers tested particles ranging from 100 nanometers to 1 micrometer and found that the largest ones were more effective. Also, as greater numbers of particles were tethered to the surface, more cells died.

The effect of the treatment appears to be specific to tumour cells and does not induce apoptosis in healthy cells, the researchers say. Michael King, a professor of biomedical engineering at Cornell University who was not involved in the research, described the approach as very creative.

“I’ve never seen another study where anyone tried to use particles attached to the cell surfaces to mechanically amplify the cells’ drug sensitivity,” says King, adding that this approach may also be applicable to other drugs.

The researchers believe that the particles may enhance TRAIL’s effects by compressing the shroud of molecules that usually surrounds tumour cells, making it easier for the drug to interact with receptors on the cell surface that turn on the cell death pathway.

“When you expose cells to forces and then these particles are coming down on the cell, they could be flattening all these molecules on the surface. Then the receptor can come in better contact with TRAIL to induce tumour cell death,” Mitchell says.

The MIT team is now exploring the possibility of using this approach in combination with other drugs that stimulate an immune response, such as drugs that induce a “cytokine storm” — a large release of signaling chemicals that attracts many immune cells to the site to destroy the tumour.

“We’re very interested in combined approaches where you can hit tumour cells with many immune-based therapies and then exploit physical forces that these cells are exposed to, as a new way to kill them,” Mitchell says.

The research was funded by a Burroughs Wellcome Fund Career Award at the Scientific Interface, a Ruth L. Kirschstein National Research Service Award, and the National Institutes of Health.

Other authors of the paper include Koch Institute postdocs Pedro Guimarães and Omar Khan, and Koch Institute technical assistants Jamie Webster and Amanda Chung.


You must be logged in to comment

Write a comment

No comments




Sign up to view our publications

Sign up

Sign up to view our downloads

Sign up

SPS IPC Drives 2017
28th November 2017
Germany Nuremberg
Cyber Security - Oil, Gas, Power 2017
29th November 2017
United Kingdom London
AI Tech World
29th November 2017
United Kingdom Olymipa, London
Maker Faire 2017
1st December 2017
Italy Rome
Virtual & Augmented Reality Creative Summit 2017
5th December 2017
United Kingdom Picturehouse Central, London